Traders should monitor cash runway and upcoming Phase 1b norovirus data readouts. Positive pipeline catalysts may offset near-term dilution risk, but limited cash runway suggests potential financing needs in 2H 2026.
Price Chart
Executive Summary
Cocrystal Pharma reported Q1 2026 EPS of -$0.17, missing consensus of -$0.15 by 13.3%, and recognized $225k in grant revenue. Pipeline progress including Phase 1b norovirus challenge study enrollment and FDA Fast Track designation for CDI-988 provides positive catalysts, but cash burn remains high with $4.7M at quarter end.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.17 vs consensus -$0.15 (miss of 13.3%)
- Revenue of $225k from NIH SBIR grant (no revenue in prior year)
- Net loss of $2.3 million, unchanged YoY on higher share count
- Cash and cash equivalents $4.7M at March 31, 2026 vs $7.7M at Dec 31, 2025
- Phase 1b norovirus challenge study enrolling; FDA Fast Track designation for CDI-988
- Weighted average shares outstanding 13.8M vs 10.2M in prior year
Financial Impact
EPS miss of 13.3% on a -$0.17 base; cash burn rate ~$2.3M per quarter with ~2 quarters of runway
Risk Factors
- Cash only sufficient for ~2 quarters at current burn rate
- Clinical trial delays or negative data could severely impact stock
- Share dilution from potential future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295782 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $1.24 | awaiting T+60 | — | $0.9700 (−21.77%) |
Aug 3, 2026 12w ago | 8-K | $0.9400 | awaiting T+60 | — | $0.9700 (+3.19%) |
Jun 9, 2026 19w ago | 8-K | $1.02 $1.16 | ▲ +13.73% | ▲ +9.91% | $0.9700 (−4.90%) |
Jun 3, 2026 20w ago | 8-K | $1.06 $1.14 | ▲ +7.55% | ▲ +5.05% | $0.9700 (−8.49%) |
May 27, 2026 21w ago | DEFA14A | $1.13 $1.15 | ▲ +1.77% | ▲ +0.03% | $0.9700 (−14.16%) |
May 26, 2026 21w ago | 8-K | $1.13 $1.15 | ▲ +1.33% | ▼ −1.40% | $0.9700 (−14.16%) |
May 15, 2026 23w ago | Press Release | $1.20 $1.08 | ▼ −10.00% | ▼ −14.52% | $0.9700 (−19.17%) |
May 4, 2026 25w ago | EFFECT | $1.31 $0.8703 | ▲ +33.56% | ▲ +35.42% | $0.9700 (+25.95%) |
Apr 2, 2026 29w ago | 8-K | $1.51 $1.05 | ▼ −30.46% | ▼ −44.62% | $0.9700 (−35.76%) |
Mar 31, 2026 29w ago | 8-K | $1.01 $1.02 | ▲ +0.99% | ▼ −11.39% | $0.9700 (−3.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers